Investor Conference Participation: Neogen Corporation will participate in the CJS Securities 26th Annual New Ideas for the New Year conference on January 14, 2026, showcasing its innovations in food safety and animal health.
Executive Speaking Engagement: CEO Mike Nassif is scheduled to present at the J.P. Morgan Healthcare Conference in San Francisco on the same day at 5:15 PM Pacific Time, which is expected to draw investor attention to the company's future developments.
Live Webcast Availability: Investors can access the live webcasts through Neogen's Investor Relations webpage, enhancing interaction and transparency between the company and its investors.
Global Market Impact: Neogen's presence in over 140 countries underscores its commitment to global food security and animal health, which is anticipated to bolster investor confidence and market influence.
NEOG
$7.09+Infinity%1D
Analyst Views on NEOG
Wall Street analysts forecast NEOG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NEOG is 8.17 USD with a low forecast of 6.50 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast NEOG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NEOG is 8.17 USD with a low forecast of 6.50 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
3 Hold
0 Sell
Hold
Current: 7.040
Low
6.50
Averages
8.17
High
10.00
Current: 7.040
Low
6.50
Averages
8.17
High
10.00
CJS Securities
Robert Labick
Market Perform -> Outperform
upgrade
$10
2025-12-10
Reason
CJS Securities
Robert Labick
Price Target
$10
2025-12-10
upgrade
Market Perform -> Outperform
Reason
CJS Securities analyst Robert Labick upgraded Neogen to Outperform from Market Perform with a $10 price target.
Piper Sandler
David Westenberg
Neutral
maintain
$5
2025-10-16
Reason
Piper Sandler
David Westenberg
Price Target
$5
2025-10-16
maintain
Neutral
Reason
Piper Sandler analyst David Westenberg raised the firm's price target on Neogen to $6.50 from $5 following quarterly results. The firm keeps a Neutral rating on the shares.
CJS Securities
initiated
$10
2025-09-29
Reason
CJS Securities
Price Target
$10
2025-09-29
initiated
Reason
CJS Securities initiated coverage of Neogen with a Market Perform rating and $10 price target.
William Blair
Outperform -> Market Perform
downgrade
2025-07-29
Reason
William Blair
Price Target
2025-07-29
downgrade
Outperform -> Market Perform
Reason
William Blair downgraded Neogen to Market Perform from Outperform. The firm had remained bullish because of what it had seen as sales and profitability growth potential, but management pointed to a worsening macro environment that resulted in fiscal 2026 revenue guidance that implies flat to declining revenues. In this context, the firm does not see "a pathway to improving markets, leaving us with tepid fiscal 2026 guidance," the analyst tells investors.
About NEOG
Neogen Corporation and subsidiaries are engaged in developing, manufacturing and marketing a diverse line of products and services dedicated to food and animal safety. The Company has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. Its segments include Food Safety and Animal Safety. The Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the development, production and marketing of products dedicated to animal safety, including a complete line of consumable products marketed to veterinarians and animal health product distributors. This segment also provides genomic identification and related interpretive bioinformatic services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
